Development of therapeutic strategy for low immunogenic tumor
| Project/Area Number |
15K18443
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 低免疫原性 / 腫瘍局所マクロファージ / 抗原提示 / 変異抗原 / 炎症 |
|---|
| Outline of Final Research Achievements |
Recently, immune checkpoint inhibitors have been emerging as novel, effective modality for the treatment of cancer. However, these inhibitors have been proven to be effective only for a partial group of patients. Although the relationship between efficacy of checkpoint inhibitors and immunogenicity of tumor has been studied, these studies paid attention only for the induction of immune responses and do not pay attention to the mechanisms regulating the anti-tumor cellular immune responses in tumor site. In this study, we explored a mechanism underlying the resistance. We revealed that tumor-associated macrophages (TAMs) remained immature and did not exert antigen-presenting activity in the resistant tumor. A nanogel-based antigen delivery system enabled to selectively and efficiently deliver a long peptide antigen to TAMs. Administration of the nanogel:long peptide antigen induced antigen presentation in TAMs. This treatment resulted in the cure of resistant tumor.
|
Report
(3 results)
Research Products
(5 results)
